Urology Centers of Alabama

Homewood, Alabama 35209-5603

8 studies enrolling now · 49 studies all time

What they study most

Androgen-insensitive Prostate Cancer, Benign Prostatic Hypertrophy, CRPC, Castration-Resistant Prostatic Cancer, Castration-resistant Prostate Cancer, Erectile Dysfunction, FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Fractures

Studies at this site

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device — Recruiting now
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. — Recruiting now
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer — Recruiting now
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer — Recruiting now
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer — Recruiting now
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) — Recruiting now
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Running, not enrolling
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC — Running, not enrolling
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — Running, not enrolling
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — Running, not enrolling
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer — Available (expanded access)
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer — Completed
Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2) — Completed
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing — Running, not enrolling
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB) — Completed
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy — Completed
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) — Completed
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer — Completed
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer — Stopped early
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients — Completed
PROPPER Prospective Registry of Outcomes With Penile Prosthesis — Completed
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer — Completed
The Cxbladder Monitoring Study — Completed
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg — Completed
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer — Completed
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma — Completed
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer — Completed
PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study — Stopped early
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy — Completed
A Trial of Degarelix in Patients With Prostate Cancer — Completed
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence — Status unconfirmed
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer — Completed
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy — Completed
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy — Completed
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer — Completed
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer — Completed
Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) — Stopped early
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer — Completed
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) — Completed
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy — Completed
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer — Completed
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer — Completed
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer — Completed
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer — Completed
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure — Completed
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer — Completed